Treatment of CMV Colitis in Severe Combined Immunodeficiency (SCID)

Initial Antiviral Therapy

The American College of Surgeons and other medical societies recommend initiating intravenous ganciclovir 5 mg/kg every 12 hours immediately upon diagnosis of CMV colitis in SCID patients, as untreated CMV disease in immunodeficient patients carries extremely high morbidity and mortality 1, 2, 3
The standard regimen for adults involves beginning IV ganciclovir 5 mg/kg every 12 hours for 3-5 days, then transitioning to oral valganciclovir 900 mg every 12 hours after initial IV therapy to complete a 2-3 week total course 1, 2, 3, 4
For pediatric SCID patients, maintain parenteral ganciclovir for the full 14-21 day course rather than switching to oral therapy, as early transition to oral treatment in children may promote CMV reactivation 1, 2, 3

Add broad-spectrum antibiotics to the antiviral regimen, as bacterial translocation and secondary infection are common complications in CMV colitis with bowel wall necrosis 1, 2, 3

Check complete blood count at least twice weekly during ganciclovir therapy, with severe neutropenia occurring in approximately 11% of ganciclovir-treated patients 5
Obtain weekly CMV viral load by PCR to assess treatment response, and continue antiviral therapy until CMV is no longer detected in blood by PCR 6
Monitor serum creatinine and electrolytes closely, particularly if foscarnet is used, due to the risk of nephrotoxicity and electrolyte abnormalities 6, 7

Proceed urgently to subtotal or partial colectomy if the patient develops toxic megacolon, fulminant colitis, colonic perforation, or bowel ischemia despite antiviral therapy 1, 2, 3
In-hospital mortality of immunocompromised patients with severe CMV colitis approaches or exceeds 70% even with treatment, emphasizing the need for early surgical consultation 1, 2, 3

Begin ganciclovir immediately when CMV colitis is suspected clinically or on endoscopy, even before histopathologic confirmation, due to the high risk of mortality and morbidity in SCID patients 1, 2, 3, 4
Do not switch to oral therapy prematurely in children, as this may promote CMV reactivation 1, 2, 3

Foscarnet may be used as an alternative agent at a dose of 90 mg/kg IV every 12 hours for treatment of established disease, particularly when ganciclovir resistance is documented or suspected 7
Cidofovir is reserved as a third-line agent due to substantial nephrotoxicity risk, and should only be considered when both ganciclovir and foscarnet have failed or are contraindicated 8, 7

The World Journal of Emergency Surgery recommends obtaining colonoscopy with multiple biopsies for histology and immunohistochemistry when clinically safe to diagnose CMV colitis in SCID patients 9, 10
CMV-specific immunohistochemistry on tissue biopsies is the gold standard diagnostic test with sensitivity of 78-93% 9, 10
Sending colonic tissue for CMV DNA PCR can improve diagnostic sensitivity, though positive PCR without histological changes may not be clinically significant 10

The World Journal of Emergency Surgery suggests that the mortality risk in untreated CMV disease in immunodeficient patients is extremely high, justifying immediate empiric treatment when CMV colitis is clinically suspected 9
Maintaining the full 14-21 day parenteral course of ganciclovir even if clinical improvement occurs earlier is recommended 9
The American College of Gastroenterology is not mentioned, however, Alimentary Pharmacology and Therapeutics recommends initiating venous thromboembolism (VTE) prophylaxis with mechanical compression devices 10

The World Journal of Emergency Surgery recommends obtaining early surgical consultation on admission given the extremely high mortality risk in SCID patients with CMV colitis 9
In-hospital mortality of immunocompromised patients with severe CMV colitis approaches or exceeds 70% even with treatment 9
Urgent subtotal or partial colectomy is indicated if the patient develops toxic megacolon, fulminant colitis, colonic perforation, or bowel ischemia 9

The World Journal of Emergency Surgery suggests admitting patients to intensive care unit or step-down unit for close monitoring due to the exceptionally high mortality risk 9
Ordering nothing by mouth (NPO) status initially with total parenteral nutrition (TPN) if prolonged bowel rest is anticipated is recommended 9